Methylphenidate hydrochloride shortage
The TGA has advised of a shortage of methylphenidate hydrochloride products, used in the treatment of attention deficit hyperactivity disorder (ADHD).
This shortage is primarily affecting methylphenidate modified-release tablets due to global manufacturing issues. Supply issues are expected to continue until further notice. The Guild understands the critical need for consistent access to methylphenidate modified-release tablets for patients and their caregivers. The shortage may cause significant concerns and challenges, especially for those relying on this medication for managing ADHD symptoms effectively. It is likely that pharmacists will need to support their patients through the shortage.
While methylphenidate modified-release tablets are currently in short supply, other forms of methylphenidate medications remain available, including immediate-release tablets, and other approved medications for treating ADHD. New prescriptions may be necessary to access alternative treatments and the Guild advises early discussions with patients, especially given the potential difficulty in scheduling appointments during the holiday season. For more information on the methylphenidate hydrochloride shortage, please see the shortage webpage on the TGA website.
This shortage is primarily affecting methylphenidate modified-release tablets due to global manufacturing issues. Supply issues are expected to continue until further notice. The Guild understands the critical need for consistent access to methylphenidate modified-release tablets for patients and their caregivers. The shortage may cause significant concerns and challenges, especially for those relying on this medication for managing ADHD symptoms effectively. It is likely that pharmacists will need to support their patients through the shortage.
While methylphenidate modified-release tablets are currently in short supply, other forms of methylphenidate medications remain available, including immediate-release tablets, and other approved medications for treating ADHD. New prescriptions may be necessary to access alternative treatments and the Guild advises early discussions with patients, especially given the potential difficulty in scheduling appointments during the holiday season. For more information on the methylphenidate hydrochloride shortage, please see the shortage webpage on the TGA website.
